In previous pre-clinical trials, MIV-210 has demonstrated very potent activity against hepatitis B virus (HBV) and has good pharmacokinetic properties, according to the companies.
MIV-210 belongs to the class of polymerase inhibitors being administered by subsidiary Medivir HIV franchise AB.